Advertisement
U.S. markets closed
Advertisement

Erasca, Inc. (ERAS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
1.8700+0.0200 (+1.08%)
At close: 04:00PM EST
1.9100 +0.04 (+2.14%)
After hours: 07:57PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Performance Outlook
Previous Close1.8500
Open1.9000
Bid1.8600 x 4000
Ask1.9100 x 3000
Day's Range1.8550 - 1.9299
52 Week Range1.5100 - 5.7600
Volume1,981,238
Avg. Volume1,008,177
Market Cap282.533M
Beta (5Y Monthly)0.79
PE Ratio (TTM)N/A
EPS (TTM)-1.7300
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.29
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ERAS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Erasca, Inc.
    Daily – Vickers Top Buyers & Sellers for 04/12/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    8 months agoArgus Research
View more
  • GlobeNewswire

    Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

    Gained alignment with global health authorities for pivotal Phase 3 SEACRAFT-2 trial design for naporafenib plus trametinib in NRAS mutant melanoma; initiation on track for H1 2024 Completed dose escalation and identified MTD for ERAS-801, supporting enrollment of expansion cohorts in recurrent GBM Extended cash runway to H1 2026 following strategic prioritization of programs SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company sin

  • GlobeNewswire

    Erasca Reports Third Quarter 2023 Financial Results and Business Updates

    First patient dosed in SEACRAFT-1 Phase 1b trial evaluating naporafenib plus trametinib Multiple upcoming catalysts across ongoing clinical programs Strong balance sheet with cash, cash equivalents, and marketable securities of $344 million as of September 30, 2023 SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driv

  • GlobeNewswire

    Erasca to Present at Upcoming Investor Conferences in November

    SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancer, today announced that management will participate in the following investor conferences in November 2023. Management will also participate in one-on-one investor meetings. Jefferies London Healthcare Conference (November 14 – 16, 2023) Location: Waldorf Hi